Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  ovarian serous cystadenocarcinoma
Stage/Subtype:  ovarian serous cystadenocarcinoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-24 of 24 for your search:
Start Over
Trametinib in Treating Patients with Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: GOG-0281, NCI-2014-00629, NCT02101788
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D0818C00001, NCI-2013-01951, NCT01844986
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D0816C00002, NCI-2014-00976, NCT01874353
Pralatrexate and Carboplatin in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-113, NCI-2011-00045, NCT01188876
A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 21
Trial IDs: M18-005, NCI-2014-01397, NCT01952249
MV-NIS Infected Mesenchymal Stem Cells in Treating Patients with Recurrent Ovarian Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1266, NCI-2014-00016, NCT02068794
Nintedanib in Treating Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Previously Treated with Bevacizumab
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00033060, NCI-2013-00455, NCT01669798
Surgery with or without Carboplatin in Treating Patients with Recurrent Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Phase: Phase II
Type: Treatment
Age: Over 21
Trial IDs: 12-275, NCI-2013-00405, NCT01767675
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CO-338-017, NCI-2013-01733, NCT01891344
Enzalutamide in Treating Patients with Advanced or Recurrent Androgen Receptor-Positive Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-119, NCI-2013-02217, NCT01974765
Gemcitabine Hydrochloride with or without WEE1 Inhibitor MK-1775 in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHL-093, NCI-2014-00620, NCI 9568, 9568, NCT02101775
Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 77
Trial IDs: UC IRB13-1235, NCI-2014-00860, IRB13-1235, NCT02122185
LY2606368 in Treating Patients with BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Non-high Risk Triple Negative Breast Cancer, or High Grade Ovarian Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0156, NCI-2014-02304, 140156, 342996, P131428, NCT02203513
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients with Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GOG-9923, NCI-2011-03730, CDR0000656038, NCT00989651
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: DNB4987g, NCI-2011-02762, GO27767, NCT01363947
PI3K Inhibitor BKM120 or PI3K Inhibitor BYL719 and Olaparib in Treating Patients with Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-159, NCI-2012-01929, NCT01623349
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients with Recurrent Glioblastoma or Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-079, NCI-2014-01118, 9552, NCT02142803
Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: 201104047, NCI-2011-00554, 10-0447, 10-0447 / 201104047, NCT01308944
Propranolol Hydrochloride and Chemotherapy in Treating Patients with Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0800, NCI-2012-00056, NCT01504126
PARP Inhibitor BMN-673 in Determining Genetic Effects on Disease Response in Patients with Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0474, NCI-2014-02608, NCT02316834
Start Over